ArticleInternational journal of clinical oncology2026
Clinical significance of secreted phosphoprotein-1 overexpression in cancers.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDysregulated SPP1 expression has been involved in the pathogenic progression of various tumors. However, more information is still necessary to understand the adverse effects of SPP1 in cancers.
methodsA systematic assessment was performed to determine the expression features of SPP1 and its clinical implications in a wide range of human cancer types. SPP1 expression was determined by implementing transcriptomic data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) projects. The prognostic value of SPP1 was assessed by Kaplan-Meier method. SPP1-related protein network was constructed using the STRING database and visualized by Cytoscape. Functional enrichment analysis was conducted through the DAVID resources. The correlation between SPP1 expression and immune infiltration was examined using TIMER and TISIDB platforms with multiple algorithms.
resultsSPP1 expression is commonly upregulated in diverse human cancers. Increased SPP1 significantly contributes to cancer progression with worse clinical outcomes. SPP1 is positively correlated with the abundance of functionally immunosuppressive lymphocytes such as regulatory T cells (Treg), myeloid-derived suppressor cells (MDSCs), M2-polarized macrophages, and cancer-associated fibroblasts (CAFs), and also associated with the upregulation of immunosuppressors such as colony-stimulating factor 1 receptor (CSF1R) and hepatitis A virus cellular receptor 2 (HAVCR2).
conclusionsElevated SPP1 recruits progressively a range of cancer pathways and contributes to poorer clinical outcomes. This study provides an integrative proof that SPP1 serves as a progressive and prognostic biomarker and a potential therapeutic target for the majority of cancer types.
Indexed as
Identifiers
42204033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.